Monoamine oxidase inhibitors

DGAP-News: Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021
European Union, Sodium channel blockers, Drugs, Multilateral development banks, Financial services, Calcium channel blockers, Monoamine oxidase inhibitors, Economy of the European Union, InvestEU, Zambon, Safinamide, European Investment Bank

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021
Professional Services, Mental Health, Health, Finance, Pharmaceutical, Biotechnology, European Union, Multilateral development banks, Sodium channel blockers, Drugs, Financial services, Calcium channel blockers, Monoamine oxidase inhibitors, Economy of the European Union, InvestEU, Safinamide, European Investment Bank, Zambon

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Companys development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Monoamine Oxidase Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Health, Pharmaceutical, Psychoactive drugs, Monoamine oxidase inhibitors, Drugs, Amphetamine, Antidepressants, Hydrazines, Reversible inhibitors of MAO-A, Monoamine neurotransmitter, Monoamine oxidase, Tetrindole, Luteusin A

The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different Monoamine Oxidase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Monoamine Oxidase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

2021 Global Hydrazine Dihydrochloride (CAS 5341-61-7) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Chemicals, Plastics, Other Manufacturing, Manufacturing, Monoamine oxidase inhibitors, Hydrazines, Hepatotoxins, Chemical substances, Chemistry, Physical sciences, Occupational safety and health, Rocket fuels, Hydrazine, Phenoxypropazine

The "Hydrazine dihydrochloride (CAS 5341-61-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrazine dihydrochloride (CAS 5341-61-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrazine dihydrochloride.
  • The Hydrazine dihydrochloride global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Hydrazine dihydrochloride market trends and forecast, distinguish Hydrazine dihydrochloride manufacturers and suppliers.

Global Hydrazine Tartrate (CAS 634-62-8) Market Research Report 2021 - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Chemicals, Plastics, Manufacturing, Enzymes, Monoamine oxidase inhibitors, Hydrazines, Hydrazine, Occupational safety and health, L(+)-tartrate dehydratase, D(-)-tartrate dehydratase, Azine, Tartrate

The "Hydrazine tartrate (CAS 634-62-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrazine tartrate (CAS 634-62-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrazine tartrate.
  • The Hydrazine tartrate global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Hydrazine tartrate market trends and forecast, distinguish Hydrazine tartrate manufacturers and suppliers.

Newron Announces 2020 Financial Results and Provides Outlook For 2021

Retrieved on: 
Tuesday, March 16, 2021
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Sodium channel blockers, Calcium channel blockers, Monoamine oxidase inhibitors, Drugs, Safinamide, Zambon, Branches of biology, Xetra, XEWW-AM, Psychoactive drugs

Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.
  • Other current financial assets) as of December 31, 2020 is EUR 31.3 million
    The onset of the COVID-19 pandemic in 2020 presented enormous challenges for societies across the world.
  • 2020 has demonstrated that Newrons business remains resilient, and we move into 2021 and beyond confident in our strategy for the future.
  • Given Newrons extensive experience in the development of Xadago/safinamide, Newron and Zambon have agreed on Newron taking responsibility for conducting the study.

DGAP-News: Newron announces 2020 financial results and provides outlook for 2021

Retrieved on: 
Tuesday, March 16, 2021
Sodium channel blockers, Calcium channel blockers, Monoamine oxidase inhibitors, Drugs, Safinamide, Zambon, Branches of biology, Xetra, Psychoactive drugs

Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Key Points: 
  • Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.
  • Other current financial assets) as of December 31, 2020 is EUR 31.3 million
    "The onset of the COVID-19 pandemic in 2020 presented enormous challenges for societies across the world.
  • 2020 has demonstrated that Newron's business remains resilient, and we move into 2021 and beyond confident in our strategy for the future.
  • Given Newron's extensive experience in the development of Xadago(R)/safinamide, Newron and Zambon have agreed on Newron taking responsibility for conducting the study.

DGAP-News: Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson's disease patients

Retrieved on: 
Monday, March 15, 2021
Neurological disorders, Branches of biology, Drugs, Parkinson's disease, Calcium channel blockers, Monoamine oxidase inhibitors, Sodium channel blockers, Safinamide, Dyskinesia, L-DOPA, Clinical trial, Parkinson's disease and Levodopa (L-dopa) Induced Dyskinesia (LID), safinamide, Newron Pharmaceuticals, Zambon

Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.

Key Points: 
  • Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.
  • Ravi Anand, CMO of Newron, said: "Previous pre-clinical and clinical studies have provided preliminary evidence of the efficacy of safinamide in reducing dyskinesia.
  • Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
  • Anand R: Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD patients as add-on to levodopa (SETTLE).

Newron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide in Parkinson’s Disease Patients

Retrieved on: 
Monday, March 15, 2021
Health, General Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Drugs, Calcium channel blockers, Monoamine oxidase inhibitors, Sodium channel blockers, Safinamide, Health, Parkinson's disease, Placebo-controlled study, Zambon

Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.

Key Points: 
  • Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.
  • Newron and Zambon will evenly share the cost of the study.
  • The double-blind, placebo-controlled study is intended to be performed in the US, Europe and Asia/Australia, with the aim of a label extension for safinamide in key markets.
  • Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.

Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea

Retrieved on: 
Monday, February 1, 2021
Branches of biology, Eisai, Monoamine oxidase inhibitors, Calcium channel blockers, Sodium channel blockers, Drugs, Medical specialties, Safinamide, Management of Parkinson's disease, Parkinson's disease

TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").

Key Points: 
  • TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").
  • The estimated number of patients with Parkinson's disease is approximately 150,000 in South Korea.
  • This disease is designated as a rare intractable disease in South Korea.
  • Together with providing Equfina as a new treatment option for Parkinson's disease to patients in South Korea, Eisai will make further contributions to address the diversified needs of Parkinson's disease patients and their families in Asia, and increase the benefits provided to them.